NasdaqGS - Nasdaq Real Time Price USD
Athira Pharma, Inc. (ATHA)
At close: November 6 at 4:00 PM EST
After hours: 7:22 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
121,399.0000
126,937.0000
88,855.0000
55,187.0000
18,674.0000
Operating Income
-121,399.0000
-126,937.0000
-88,855.0000
-55,187.0000
-18,674.0000
Net Non Operating Interest Income Expense
--
--
--
334.0000
-243.0000
Other Income Expense
7,948.0000
9,265.0000
-6,784.0000
334.0000
-1,038.0000
Pretax Income
-113,451.0000
-117,672.0000
-95,639.0000
-54,853.0000
-19,955.0000
Net Income Common Stockholders
-113,451.0000
-117,672.0000
-95,639.0000
-55,274.0000
-19,955.0000
Diluted NI Available to Com Stockholders
-113,451.0000
-117,672.0000
-95,639.0000
-55,274.0000
-19,955.0000
Basic EPS
-2.97
-3.09
-2.53
-1.49
-1.67
Diluted EPS
-2.97
-3.09
-2.53
-1.49
-1.67
Basic Average Shares
38,214.6580
38,020.1820
37,733.2400
36,921.1720
11,966.9120
Diluted Average Shares
38,214.6580
38,020.1820
37,733.2400
36,921.1720
11,966.9120
Total Operating Income as Reported
-119,771.0000
-125,466.0000
-104,016.0000
-64,022.0000
-19,995.0000
Total Expenses
121,399.0000
126,937.0000
88,855.0000
55,187.0000
18,674.0000
Net Income from Continuing & Discontinued Operation
-113,451.0000
-117,672.0000
-95,639.0000
-54,853.0000
-19,955.0000
Normalized Income
-115,079.0000
-119,300.0000
-85,639.0000
-54,853.0000
-19,381.0000
Interest Income
--
--
--
337.0000
124.0000
Interest Expense
--
--
--
3.0000
367.0000
Net Interest Income
--
--
--
334.0000
-243.0000
EBIT
-121,399.0000
-126,937.0000
-88,855.0000
-55,187.0000
-19,588.0000
EBITDA
-120,426.0000
-125,968.0000
-88,010.0000
-54,708.0000
-19,586.0000
Reconciled Depreciation
973.0000
969.0000
845.0000
479.0000
2.0000
Net Income from Continuing Operation Net Minority Interest
-113,451.0000
-117,672.0000
-95,639.0000
-54,853.0000
-19,955.0000
Total Unusual Items Excluding Goodwill
1,628.0000
1,628.0000
-10,000.0000
--
-574.0000
Total Unusual Items
1,628.0000
1,628.0000
-10,000.0000
--
-574.0000
Normalized EBITDA
-122,054.0000
-127,596.0000
-78,010.0000
-54,708.0000
-19,012.0000
12/31/2020 - 9/18/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
TOVX Theriva Biologics, Inc.
1.9700
0.00%
BNOX Bionomics Limited
0.2789
-43.43%
ENSC Ensysce Biosciences, Inc.
0.5503
+5.42%
THAR Tharimmune, Inc.
2.8000
+1.08%
ZVSA ZyVersa Therapeutics, Inc.
1.5400
-39.37%
GLYC GlycoMimetics, Inc.
0.3765
-3.46%
GRI GRI Bio, Inc.
0.9500
-4.04%
NLSP NLS Pharmaceutics AG
4.0900
+1.24%
ELAB Elevai Labs Inc.
0.0178
-16.82%
EPIX ESSA Pharma Inc.
1.7100
+0.59%